Ronapreve (Note 2) Initial Approval
Casirivimab (genetical recombination) and imdevimab (genetical recombination)
Approval Information
Brand NameRonapreve (Note 2)
Initial Approval
Generic NameCasirivimab (genetical recombination) and imdevimab (genetical recombination)
ApprovedJuly 2021
TypeInitial Approval
Review Reports
Want structured data, translation summaries & alerts?
PharmaLens is building the most comprehensive English-language PMDA intelligence platform. Join the waitlist for early access.
Join the WaitlistSource: PMDA Website. Review reports are provided under Japan's Public Data License v1.0. Translations and structured data by PharmaLens are unofficial and for reference only.